ImageneBio Inc
NASDAQ: IMA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kristin Yarema
- Employees
- 10
- Headquarters
- San Diego, United States
- IPO year
- 1998
- Market cap
- $67.7M
- Website
- https://www.inmagenebio.com
Loading IMA…
Loading profile data…Frequently asked questions about IMA
What does ImageneBio Inc (IMA) do?
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical...
Where does IMA trade?
ImageneBio Inc (IMA) trades on the NASDAQ Global Market.
What sector is IMA in?
ImageneBio Inc (IMA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ImageneBio Inc?
Kristin Yarema is the chief executive officer of ImageneBio Inc (IMA).
Where is ImageneBio Inc headquartered?
ImageneBio Inc is headquartered in United States.
Does IMA pay a dividend?
ImageneBio Inc (IMA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMA go public?
ImageneBio Inc (IMA) completed its initial public offering in 1998.